Search

Author/Creator Repp, Roland

1. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Issue 16 (December 2015)

Authors:
Röllig, Christoph; Serve, Hubert; Hüttmann, Andreas; Noppeney, Richard; Müller-Tidow, Carsten; Krug, Utz; Baldus, Claudia D; Brandts, Christian H; Kunzmann, Volker; Einsele, Hermann; Krämer, Alwin; Schäfer-Eckart, Kerstin; Neubauer, Andreas; Burchert, Andreas; Giagounidis, Aristoteles; Krause, St...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 16(2015)
Page Start:
1691
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. (2nd January 2016)

Authors:
Kellner, Christian; Günther, Andreas; Humpe, Andreas; Repp, Roland; Klausz, Katja; Derer, Stefanie; Valerius, Thomas; Ritgen, Matthias; Brüggemann, Monika; van de Winkel, Jan GJ; Parren, Paul WHI; Kneba, Michael; Gramatzki, Martin; Peipp, Matthias
Journal:
Oncoimmunology
Issue:
Volume 5:Number 1(2016)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search